
Rolf Classon Appointed Chairman of the Board of Management of Bayer HealthCare AG

Dr. Frank Morich Leaves Bayer

Leverkusen, October 28, 2002 – The Board of Management of Bayer AG has appointed Rolf Classon the new Chairman of the Board of Management of the future Bayer HealthCare AG effective immediately. In addition, he will also assume the chairmanship of Bayer HealthCare's Executive Committee.

Classon succeeds Dr. Frank Morich, who has left Bayer AG by mutual agreement.

The new HealthCare CEO was previously a member of the subgroup's Executive Committee, in which he was responsible for strategy and business development. In addition, he was Head of the Diagnostics Division of Bayer HealthCare.

Rolf Classon joined Bayer in 1991 as Executive Vice President of the Diagnostics Business Group, responsible for marketing, sales and service. On January 1, 1995, he became head of the business group, which is headquartered in the United States.

Among his accomplishments at Bayer, Classon was responsible for the successful integration of the diagnostics activities of Chiron into Bayer's Diagnostics Division. Prior to joining Bayer, he held various managerial posts at Pharmacia AB, a Swedish health care company. Classon was born in Sweden.

Professor Dr. Wolfgang Hartwig will assume the position of Head of the Diagnostics Division with immediate effect. As previously announced, he has been preparing to take up his new post for the past several weeks.

Prof. Dr. Wolfgang Hartwig began working at Bayer in 1982. He became a head of department in 1988 and was appointed head of the Pharmaceuticals Business Group's chemical laboratory three years later. In 1993, he transferred to the Bayer Corporation in the US as Head of Pharmaceutical Research. From the end of 1996 to mid 2002, Hartwig headed the global research activities of the Pharmaceuticals Business Group. On July 1, he transferred within the HealthCare business area to the Diagnostics Division.

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.